Patents Issued in October 6, 2016
-
Publication number: 20160289260Abstract: The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also provides novel crystalline forms of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof (Form A, Form B, and Form C), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.Type: ApplicationFiled: November 2, 2015Publication date: October 6, 2016Inventor: Edward J. Olhava
-
Publication number: 20160289261Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes.Type: ApplicationFiled: December 11, 2014Publication date: October 6, 2016Inventors: Vivek Arora, Charles L. Sawyers, Michael J. Evans, Darren R. Veach
-
Publication number: 20160289262Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.Type: ApplicationFiled: March 30, 2016Publication date: October 6, 2016Inventors: Guoqiang Wang, Yat Sun Or, Ruichao Shen, Xuechao Xing, Jiang Long, Peng Dai, Brett Granger, Jing He
-
Publication number: 20160289263Abstract: The present invention relates to a method of synthesizing a peptide product comprising at least one cyclic imide group. Further, the invention relates to a peptide product comprising at least one cyclic imide group, which is substantially free from degradation products. The peptide product may be used as a reference material for the quality control of pharmaceutical peptides, particularly for the quality control of a GLP-1 agonist like exendin peptides.Type: ApplicationFiled: March 19, 2014Publication date: October 6, 2016Inventor: Bernd Henkel
-
Publication number: 20160289264Abstract: A method is provided for purifying a recombinant protein from a mixture comprising the recombinant protein and related proteins, comprising the steps of: A. using a first equilibrating buffer in a first conductivity and pH to make the recombinant protein bind to an ion exchange medium; B. using a second equilibration buffer in a second conductivity and pH to continually equilibrate the ion exchange medium bound to the protein; C. using a washing liquid in a third conductivity and a gradually increasing pH to wash the ion-exchange medium, and eluting the first category-related proteins; D. using a first eluent in a fourth conductivity and pH to elute the ion exchange medium, and eluting the target recombinant protein; and E. using a second eluent in a fifth conductivity and pH to continually elute the ion exchange medium, and eluting the second category-related proteins.Type: ApplicationFiled: November 3, 2014Publication date: October 6, 2016Inventors: Hui HU, Yunbin ZHU, Meiling ZANG
-
Publication number: 20160289265Abstract: The invention relates to a method for the preparation of an application buffer for the purification of proteins by means of immobilized metal ion affinity chromatography (IMAC) under denaturing conditions, which is characterized in that a defined amount of a buffer concentrate having a defined pH value is mixed with a defined amount of a urea concentrate, whereby an application buffer having a defined pH value is provided. According to the invention, a corresponding kit is provided in addition. The components are stable in storage and by mixing produce an application buffer having a defined composition and a defined pH value. The need for pH adjustment or a new preparation is eliminated. The invention can thus be used in an automated manner and as a closed kit concept.Type: ApplicationFiled: April 4, 2016Publication date: October 6, 2016Inventors: Thomas Deutschmann, Frank Schaefer, Helena Block
-
Publication number: 20160289266Abstract: The invention relates to a method for reducing colour of a biotechnological liquid. In the method a biotechnological liquid comprising colour forming substances is obtained and a high-basicity aluminium compound, which has a basicity of at least 0%, is added and mixed to the biotechnological liquid. Precipitate and/or flocks comprising colour forming substances are allowed to form, and the precipitate and/or flocks are separated from the biotechnological liquid.Type: ApplicationFiled: November 5, 2014Publication date: October 6, 2016Applicant: Kemira OyjInventors: Susanna HOLAPPA, Michael RECKTENWALD
-
Publication number: 20160289267Abstract: The present invention relates to a method for concentrating von Willebrand Factor (VWF) from an aqueous solution comprising precipitating the VWF by providing calcium ions and phosphate ions and the subsequent resolubilization of the VWF by means of an aqueous solution comprising a calcium complexing compound.Type: ApplicationFiled: November 7, 2014Publication date: October 6, 2016Applicant: CSL LimitedInventors: Holger LIND, Sonja BECKMANN-SCHELD, Katharina PROPP
-
Publication number: 20160289268Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).Type: ApplicationFiled: January 14, 2016Publication date: October 6, 2016Applicants: United Therapeutics Corporation, The U.S.A. as represented by the Secretary, Department of Health and Human ServicesInventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
-
Publication number: 20160289269Abstract: The invention includes an isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell. The invention also includes a transport construct in which a transport peptide is linked to a cargo moiety to be delivered into a cell. The invention further includes a method of delivering a transport construct into and/or to a cell.Type: ApplicationFiled: November 20, 2014Publication date: October 6, 2016Applicant: Yale UniversityInventors: William C. SESSA, Frank J. GIORDANO
-
Publication number: 20160289270Abstract: Provided is an isolated peptide or a peptidomimetic comprising a sequence corresponding to amino acid positions 431-616 or 411-616 of the human protein TLR4 or corresponding to amino acid positions 84-131 of the human protein MD-2. Provided is also an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 411 to 616 of variant 1 the human protein TLR4. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 86 to 131 of the human protein MD2. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between one of the above peptides or whole molecules and an S100A8 or S100A9 or S100A8/S100A9 protein or a functional fragment thereof.Type: ApplicationFiled: November 17, 2014Publication date: October 6, 2016Applicant: Westfaelische Wilhelms-Universitaet MuensterInventors: Johannes Roth, Thomas Vogl
-
Publication number: 20160289271Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.Type: ApplicationFiled: March 17, 2016Publication date: October 6, 2016Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
-
Publication number: 20160289272Abstract: The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents.Type: ApplicationFiled: November 6, 2014Publication date: October 6, 2016Inventors: Marit Otterlei, Siri Bachke
-
Publication number: 20160289273Abstract: The present invention provides a fusion compound comprising a procoagulant compound and an immunoglobulin constant region or a portion thereof and methods of making and using the fusion compound. The fusion compounds of the present disclosure are useful for the treatment of coagulation disorders, such as hemophilia. In some aspects, the invention includes a method of reducing or preventing aggregates which comprise a procoagulant compound comprising fusing the procoagulant compound to an immunoglobulin constant region or a portion thereof wherein the procoagulant compound comprises an amino acid sequence. In another embodiment, the fusion compound forms less aggregates compared to a compound consisting of the procoagulant compound.Type: ApplicationFiled: November 7, 2014Publication date: October 6, 2016Applicant: Biogen MA Inc.Inventor: Karina THORN
-
Publication number: 20160289274Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.Type: ApplicationFiled: April 7, 2016Publication date: October 6, 2016Inventor: Huw M. Nash
-
Publication number: 20160289275Abstract: A modified adeno-associated virus (AAV) capsid protein comprising at least one non-native amino acid that confers to the modified AAV particles new properties, such as increased transduction efficiency and reduced immunogenicity. These modified AAV proteins and particles are particularly useful for gene therapy and the treatment of various diseases and conditions.Type: ApplicationFiled: April 6, 2016Publication date: October 6, 2016Inventors: John A. Chiorini, Sandra Wainer, Mavis Agbandje-McKenna, Sujata Halder
-
Publication number: 20160289276Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.Type: ApplicationFiled: April 11, 2016Publication date: October 6, 2016Inventors: Chang Soo Hong, Tohru Yamada, Arsenio M. Fialho, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Publication number: 20160289277Abstract: Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine and canine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of a coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous coagulation factor protein.Type: ApplicationFiled: November 17, 2014Publication date: October 6, 2016Inventors: Roland W. HERZOG, Henry DANIELL
-
Publication number: 20160289278Abstract: The invention relates to the polynucleotide sequence of a nontypeable strain of Haemophilus influenza (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: ApplicationFiled: June 9, 2016Publication date: October 6, 2016Inventors: Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
-
Publication number: 20160289279Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: June 21, 2016Publication date: October 6, 2016Inventors: Kimberly Brown, Paul Harris, Elizabeth Zaretsky, Edward Re, Elena Vlasenko, Keith McFarland, Alfredo Lopez de Leon
-
Publication number: 20160289280Abstract: The present invention relates to a field of biological pharmacy, wherein a fusion protein rLZ-8 of a ganoderma immunoregulatory protein and HSA prepared with gene engineering technologies, a preparation method thereof and applications thereof are disclosed. Compared with rLZ-8, a half-life of the fusion protein is prolonged, and biological activity thereof is increased. The fusion protein is applicable to drugs in treatment of leucopenia and anti-tumor.Type: ApplicationFiled: July 11, 2014Publication date: October 6, 2016Inventors: Xitian ZHANG, Fei SUN
-
Publication number: 20160289281Abstract: The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerisation therapy.Type: ApplicationFiled: April 11, 2016Publication date: October 6, 2016Inventors: Roderick Peter HAFNER, Mark LARCHE
-
Publication number: 20160289282Abstract: The present invention relates to a method of synthesizing a peptide product comprising at least one hydantoin group. The peptide product may be used as a reference material for the quality control of pharmaceutical peptides, particularly for the quality control of exendin peptides. Further, the invention relates to hydantoin building blocks, a method for manufacturing such building blocks and their use for the synthesis of peptide products.Type: ApplicationFiled: March 19, 2014Publication date: October 6, 2016Inventor: Bernd Henkel
-
Publication number: 20160289283Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.Type: ApplicationFiled: November 13, 2014Publication date: October 6, 2016Applicant: Novo NordiskInventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
-
Publication number: 20160289284Abstract: The present invention relates to proteins consisting of an artificial DNA-binding domain (DBD) and related molecules and uses thereof. In particular, the proteins are ZF-DBD or TALE-DBD and are used for the treatment of eye disorders caused by gain of function mutation. The disorder may be ADRP, in particular ADRP caused by mutation in the rhodopsin gene. The present invention also relates to a method to identify cis-regulatory elements and to modulate them via DBDs.Type: ApplicationFiled: November 20, 2014Publication date: October 6, 2016Inventors: Salvatore BOTTA, Enrico Maria SURACE, Elena MARROCCO
-
Publication number: 20160289285Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: April 1, 2016Publication date: October 6, 2016Inventors: Talitha BAKKER, Michael T. STUMPP, Hans Kaspar BINZ, Douglas PHILLIPS, Ignacio DOLADO, Patrik FORRER, Frieder W. MERZ, Ivo SONDEREGGER, Daniel STEINER, Maya GULOTTI-GEORGIEVA, Johan ABRAM SALIBA
-
Publication number: 20160289286Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sideroblastic anemias and myelodysplastic syndromes or one or more complications associated sideroblastic anemias and myelodysplastic syndromes.Type: ApplicationFiled: December 3, 2015Publication date: October 6, 2016Inventors: Kenneth M. Attie, Christopher Robert Rovaldi
-
Publication number: 20160289287Abstract: The present invention relates generally to peptides and more specifically to anti-biofilm and immunomodulatory peptides.Type: ApplicationFiled: August 27, 2014Publication date: October 6, 2016Applicant: The University of British ColumbiaInventors: Robert E.W. Hancock, Cesar de la Fuente Nunez, Jason Kindrachuk, Havard Jenssen, Joerg Overhage, Evan Haney
-
Publication number: 20160289288Abstract: The subject invention pertains to agonist peptides of type I interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the C-terminus region of the type I IFN molecules and are capable of binding to the cytoplasmic domain of type I IFN receptors. Surprisingly, these peptides were found to possess the same or similar biological activity as that associated with the full-length, mature type I IFN proteins, even though these peptides do not bind to the extracellular domain of the type I IFN receptors. In one embodiment, the peptide is a peptide of IFN?. In another embodiment, the peptide is a peptide of IFN?. Exemplified peptides of the invention include those having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. The subject peptides have been shown to effect increased resistance to viral infection.Type: ApplicationFiled: December 11, 2014Publication date: October 6, 2016Inventors: HOWARD M. JOHNSON, CHULBUL M. AHMED
-
IDENTIFICATION OF A NEW POLYPEPTIDE HORMONE FOR MAINTENANCE OF OPTIMAL BODY WEIGHT AND BLOOD GLUCOSE
Publication number: 20160289289Abstract: Embodiments of the disclosure concern methods and compositions that relate to increasing or decreasing the weight (including, for example, by increasing or decreasing the adipose mass) in individuals in need thereof. Such methods and compositions, in particular embodiments, concern providing an effective amount of the hormone asprosin to increase adipose mass in an individual with insufficient adipose mass and providing an antibody or inhibitor of asprosin in an individual with obesity or diabetes, for example, to reduce adipose mass.Type: ApplicationFiled: November 24, 2014Publication date: October 6, 2016Applicants: Baylor College of Medicine, Baylor College of MedicineInventors: Atul Chopra, David D. Moore -
Publication number: 20160289290Abstract: Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1-9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(1-4)GlcNAc(1-4)Man3GlcNAc2; or selected from N-glycans in the group consisting of NANA(1-4)Gal(1-4)GlcNAc(1-4)Man3GlcNAc2.Type: ApplicationFiled: January 14, 2016Publication date: October 6, 2016Inventors: Michael Meehl, Natarajan Sethuraman, Sandra Rios
-
Publication number: 20160289291Abstract: Novel proinsulins and glargine, aspart and Lis-Pro proinsulin analogs having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production, as well as novel and highly efficient processes for preparing the same. The novel proinsulins and proinsulin analogs may be converted into human insulin and insulin analogs, respectively, that are useful in therapeutic preparations.Type: ApplicationFiled: January 27, 2016Publication date: October 6, 2016Inventors: Ronald E. ZIMMERMAN, David John STOKELL, Michael Patrick AKERS
-
Publication number: 20160289292Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.Type: ApplicationFiled: April 6, 2016Publication date: October 6, 2016Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
-
Publication number: 20160289293Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.Type: ApplicationFiled: November 21, 2014Publication date: October 6, 2016Inventors: Martin Pulé, Khai Kong, Shaun Cordoba
-
Publication number: 20160289294Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.Type: ApplicationFiled: November 21, 2014Publication date: October 6, 2016Inventors: Martin Pulé, Khai Kong, Shaun Cordoba
-
Publication number: 20160289295Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.Type: ApplicationFiled: December 7, 2014Publication date: October 6, 2016Inventors: Raymond KAEMPFER, Anat SHIRVAN, Gila ARAD
-
Publication number: 20160289296Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: March 28, 2016Publication date: October 6, 2016Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH, Colette SONG
-
Publication number: 20160289297Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.Type: ApplicationFiled: July 28, 2014Publication date: October 6, 2016Applicant: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Shahid Nimjee, Sabah Oney, Nanette Que-Gewirth
-
Publication number: 20160289298Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer.Type: ApplicationFiled: April 6, 2016Publication date: October 6, 2016Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako
-
Publication number: 20160289299Abstract: The present application generally relates to methods to prevent or treat bleeding and/or hypocoagulation in an individual in need thereof, and compositions for use in such methods. The methods comprise administration of FVa, preferably an APC resistant FVa (such as superFVa), alone or in combination with FVIIa, preferably rhFVIIa (such as NovoSeven® or another FVIIa having enhanced activity or half-life). When administered in combination, FVa and FVIIa elicit a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, e.g.Type: ApplicationFiled: November 4, 2014Publication date: October 6, 2016Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: John H. GRIFFIN, Laurent MOSNIER, Annette VON DRYGALSKI, Andrew GALE
-
Publication number: 20160289300Abstract: The present subject matter is directed to a method of manufacturing purified IVIG from Fraction III of plasma, comprising re-constituting a Fraction III paste in a buffer; adjusting the pH and temperature; adding ethanol and then gradually lowering the temperature; centrifuging and filtering the supernatant; ultra-filtrating to remove alcohol; undergoing weak anion exchange chromatography; ultra-filtrating to reach a desired protein concentration; aseptic filtrating; nano filtrating for virus removal; and incubating at low pH for virus inactivation to obtain a resulting Fraction III suspension comprising purified IVIG. The present subject matter is directed to IVIG having 14 newly-found proteins, namely KH 26, KH 27, KH 28, KH 29, KH 30, KH 31, KH 32, KH 33, KH 39, KH 40, KH 41, KH 42, KH 43, and KH 44 for both liquid and lyophilized form.Type: ApplicationFiled: April 4, 2016Publication date: October 6, 2016Inventor: Kieu Hoang
-
Publication number: 20160289301Abstract: The present subject matter is directed to a process of cloning and purifying recombinant intravenous immunoglobulin (IVIG), comprising cloning a target gene of human immunoglobulin; in vitro screening of a yeast cell expressing the target gene of human immunoglobulin to create a yeast cell line; fermenting the yeast cell line and collecting a resulting culture medium; filtering the culture medium; undergoing weak anion exchange chromatography to collect a flow-through solution; ultra-filtrating the flow-through solution to reach a desired protein concentration; aseptic filtrating the flow-through solution; nano filtrating the flow-through solution for virus removal; and filling and incubating the flow-through solution at low pH for virus inactivation to obtain a purified recombinant IVIG. The present subject matter is directed to purified recombinant IVIG having five newly-found proteins, namely KH 33, KH 34, KH 35, KH 36, and KH 37 for both liquid and lyophilized forms.Type: ApplicationFiled: April 4, 2016Publication date: October 6, 2016Inventor: Kieu Hoang
-
Publication number: 20160289302Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.Type: ApplicationFiled: November 11, 2015Publication date: October 6, 2016Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20160289303Abstract: Provided herein are compositions and methods for the treatment of HCMV infection in a subject.Type: ApplicationFiled: November 14, 2014Publication date: October 6, 2016Inventors: MICHAEL P. WEEKES, STEVEN P. GYGI, PAUL J. LEHNER, GAVIN W. WILKINSON, PETER TOMASEC, RICHARD J. STANTON
-
Publication number: 20160289304Abstract: The invention provides antibody reagents for screening for seed viruses, in particular, antibodies that bind to one or more discontinuous epitopes in hemagglutinin (HA) polypeptide of human influenza virus (H1N1 strain). Additionally, the invention relates to compositions, kits, supports, and biologicals comprising the antibodies or fragments thereof. Also provided are nucleic acids encoding such antibodies or fragments, including, cells and/or hybridomas which generate such molecules. Additional embodiments relate to the immunogens useful in generating the antibodies, including nucleic acids encoding such immunogens, and compositions comprising such immunogens. Further embodiments relate to methods for screening for seed viruses, including human influenza type A virus seed viruses, using the antibodies or fragments thereof.Type: ApplicationFiled: March 30, 2016Publication date: October 6, 2016Applicant: VIRO DYNAMICS CORPORATIONInventors: Doris BUCHER, Yu HE, Jianhua LE, Manojkumar RAMANUNNINAIR
-
Publication number: 20160289305Abstract: The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.Type: ApplicationFiled: April 19, 2016Publication date: October 6, 2016Inventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang
-
Publication number: 20160289306Abstract: An object of the present invention is to provide a Fab region-binding peptide having an excellent ability for binding to a Fab region of IgG, an affinity separation matrix having the peptide as a ligand, and a method for producing a Fab region-containing protein, the method using the affinity separation matrix. Further, another object of the present invention is to provide a DNA encoding for the peptide, a vector containing the DNA, and a transformant which has been transformed by the vector. The Fab region-binding peptide according to the present invention is characterized in having a mutation at a specific site in comparison with wild-type SpG-?1.Type: ApplicationFiled: August 28, 2014Publication date: October 6, 2016Applicant: KANEKA CORPORATIONInventors: Shinichi YOSHIDA, Dai MURATA
-
Publication number: 20160289307Abstract: The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.Type: ApplicationFiled: April 9, 2014Publication date: October 6, 2016Applicant: LYKERA BIOMED SAInventors: José Luis HERNÁNDEZ MÍGUEZ, Jaume ADAN PLANA, Josep Maria MARTÍNEZ ESCOLÀ, Marc MASA ÁL VAREZ, Ramon MESSEGUER PEYPOCH, Francesc MITJANS PRAT, Sheila DAKHEL PLAZA, Antonio COLL MANZANO, Rosa Mª HERVAS VILLEGAS, Carme CALVIS CALPE, Laura PADILLA GARCÍA, Lourdes Tatiana ROQUE NAVARRO, Laura BARBERÀ FERRANDO, Manuel RIVAS CANAS
-
Publication number: 20160289308Abstract: The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.Type: ApplicationFiled: November 6, 2014Publication date: October 6, 2016Inventors: Ravi A. VIJAYENDRAN, Srivatsa VENKATASUBBARAO
-
Publication number: 20160289309Abstract: The present disclosure provides methods for treating a tauopathy (e.g., an acute tauopathy) in an individual by administering an anti-Tau antibody to the individual. Also provided are methods of treating traumatic brain injury and methods of treating stroke in an individual by administering an anti-Tau antibody to the individual.Type: ApplicationFiled: November 25, 2014Publication date: October 6, 2016Applicant: IPIERIAN, INC.Inventors: Irene GRISWOLD-PRENNER, Graham PARRY